(Q42963970)

English

A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).

scientific article published on 19 June 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Ming-Sound Tsao

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

H Hirte

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A Oza

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

K Swenerton

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

R Grimshaw

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

B Fisher

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

L Seymour

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

language of work or name

0 references

publication date

19 June 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

118

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

308-312

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Clinical trials in patients with epithelial ovarian cancer: past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Epidermal growth factor receptor and bladder cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Expression of epidermal growth factor and androgen receptors in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Epidermal growth factor receptors (EGFR) in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa").

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Epithelial growth factor receptor status in primary and recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.05.005

7 January 2021

Identifiers

10.1016/J.YGYNO.2010.05.005

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20646751%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42963970&oldid=2076364962"